drugset
drugset / Trial / NCT04634136

Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy

NCT04634136 ↗

Completed 55 enrolled University Medical Centre Ljubljana PharmaHemp · collabUniversity of Ljubljana, Faculty of Medicine · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The proposed study is a double-blind, placebo-controlled, cross over study on 60 children aged 5 to 25 years with severe spasticity related to cerebral palsy (CP), level IV and V with full-spectrum medical cannabis product of CBD/THC ratio 10:1.

Timeline

Start
2020-10-15
Primary completion
2023-12-01
Completion
2024-02-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator HemPhar Unknown 1 mg/kg Oral

Indications

spastic cerebral palsy